In the clinical study, the prophylactic efficacy of RIXUBIS® was studied in 56 previously treated patients (PTPs) between 12 and 65 years of age with severe or moderately severe hemophilia B for a mean treatment duration of 6.2 ± 0.7 months. 1,2

43%

of patients
≥12 Years of age

experienced zero bleeds on RIXUBIS prophylactic treatment1,2


In the pediatric study, the prophylactic efficacy of RIXUBIS® was studied in 23 PTPs between 1.8 and 11.8 years with severe or moderately severe hemophilia B for a mean treatment duration of 7.7 ± 1.08 months.1,3

39%

of patients
<12 Years of age

experienced zero bleeds on RIXUBIS prophylactic treatment1,3

SEE STORIES
RIXUBIS [Coagulation Factor IX (Recombinant)] news

News and updates

SIGN UP
You may be eligible to try RIXUBIS [Coagulation Factor IX (Recombinant)] for free

See if you are eligible to try RIXUBIS® for free today

GET STARTED
RIXUBIS [Coagulation Factor IX (Recombinant)] cost

Need help paying for RIXUBIS?

LEARN MORE
Contact your local representative

Meet your local representative

CONNECT
43%
of patients experienced zero bleeds during 6 months of RIXUBIS prophylactic treatment*1
  • *Prophylaxis efficacy of RIXUBIS was studied in 56 previously treated patients between 12 and 65 years of age with severe or moderately severe hemophilia B for a mean treatment duration of 6 months.1